Delivery Order SPE2DB22D2206-SPE2DB24FFS51
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Advair HFA 115-21 MCG Inhaler 12GM. The $4,571.62 firm fixed-price delivery order has an ultimate completion date of January 4, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC...
- The federal contract award is to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Advair HFA 115-21 MCG Inhaler 12GM to the Defense Logistics Agency (DLA). The Firm Fixed Price delivery order, valued at $4,701.81, has an ultimate completion date of March 1, 2024. This contract is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC enables...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Advair HFA 115-21 mcg inhalers. The $25,074.96 firm fixed-price delivery order contract has a completion date of May 6, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) under a Delivery Order valued at $6,654.52. The contract provides for the delivery of Advair HFA 115-21 MCG Inhaler 12GM, a pharmaceutical product, with a period of performance through February 28, 2024. The contract is a Firm Fixed Price type and was awarded without a set-aside designation, indicating full and open competition. Amerisourcebergen Drug Corp...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,137.64 firm fixed-price delivery order is for the supply of ADVAIR HFA 115-21 MCG INHALER 12GM, a pharmaceutical product. The contract has an ultimate completion date of March 7, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026....
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) for the delivery of Advair HFA 230-21 MCG inhalers. The firm-fixed-price delivery order, valued at $15,070.88, has an ultimate completion date of April 3, 2024. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Advair HFA 230-21 MCG inhalers. The $1,688.82 firm-fixed-price contract has an ultimate completion date of August 17, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Advair HFA 115-21 MCG Inhaler 12GM, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $13,505.54 and an ultimate completion date of January 26, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. The award was made without a set-aside designation, indicating open competition....
- This federal contract award, valued at $11,679.54, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Advair HFA 230-21 MCG inhalers, a pharmaceutical product used for the treatment of respiratory conditions. This is a firm-fixed-price delivery order contract with a completion date of February 13, 2024. The contract was awarded on an open competition basis, with no set-aside designations....
- This federal contract award, valued at $2,801.77, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of an Advair HFA 115-21 MCG Inhaler, a pharmaceutical product. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FFS51Delivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Advair HFA 115-21 MCG Inhaler 12GM. The firm-fixed-price delivery order, valued at $6,775.41, has a completion date of February 22, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. The contract award was made under full and open competition, with no set-aside designation. Amerisourcebergen's extensive experience in pharmaceutical distribution and its established relationship with the DLA through the IDC demonstrate its ability to efficiently fulfill the government's requirements for essential medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.8k | 2/21/24 |